Over the last 7 days, the United States market has remained flat, yet it is up 5.7% over the past year with earnings forecasted to grow by 13% annually. In this context of steady growth, identifying ...

In a report released today, Vamil Divan from Guggenheim maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...

Over the last 7 days, the United States market has experienced a 3.0% drop, although it has risen by 4.6% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

Armistice Capital lost almost 19% last month, the biggest decline for the hedge fund’s flagship money pool since its launch ...

That includes Perspective Therapeutics (CATX), Indie Semiconductor (INDI), and Travere Therapeutics (TVTX). These three are the top stocks listed on the Analyst Top Stocks tool. CATX could increase by ...

Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an ...